CD274 and neoplasm: Regarding CRC, in patients with microsatellite-stable (MSS) CRC who do not respond to IC inhibitors, anti-tumor activity of the HDACi CXD101 and nivolumab (anti-PD-L1) was assessed in a phase II clinical trial (Table 4) and showed good tolerance and efficacy in the treatment of advanced MSS CRC [186].